Mitochondrial disorders are a group of pathologies characterized by impairment of mitochondrial function mainly due to defects of the respiratory chain and consequent organellar energetics. This affects organs and tissues that require an efficient energy supply, such as brain and skeletal muscle. They are caused by mutations in both nuclear-and mitochondrial DNA (mtDNA)-encoded genes and their clinical manifestations show a great heterogeneity in terms of age of onset and severity, suggesting that patient-specific features are key determinants of the pathogenic process. In order to correlate the genetic defect to the clinical phenotype, we used a cell culture model consisting of fibroblasts derived from patients with different mutations in the mtDNA-encoded ND5 complex I subunit and with different severities of the illness. Interestingly, we found that cells from patients with the 13514A4G mutation, who manifested a relatively late onset and slower progression of the disease, display an increased autophagic flux when compared with fibroblasts from other patients or healthy donors. We characterized their mitochondrial phenotype by investigating organelle turnover, morphology, membrane potential and Ca 2+ homeostasis, demonstrating that mitochondrial quality control through mitophagy is upregulated in 13514A4G cells. This is due to a specific downregulation of mitochondrial Ca 2+ uptake that causes the stimulation of the autophagic machinery through the AMPK signaling axis. Genetic and pharmacological manipulation of mitochondrial Ca 2+ homeostasis can revert this phenotype, but concurrently decreases cell viability. This indicates that the higher mitochondrial turnover in complex I deficient cells with this specific mutation is a pro-survival compensatory mechanism that could contribute to the mild clinical phenotype of this patient. Mitochondrial disorders include a wide range of pathological conditions characterized by defects in organelle homoeostasis and energy metabolism, in particular in the electron transport chain (ETC) complexes. They are mostly caused by mutations in nuclear-or mtDNA-encoded genes of the respiratory chain complexes leading to a variety of clinical manifestations, ranging from lesions in specific tissues, such as in Leber's hereditary optic neuropathy, to complex multisystem syndromes, such as myoclonic epilepsy with ragged-red fibers, Leigh syndrome or the mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome (MELAS).
Mitochondrial disorders are a group of pathologies characterized by impairment of mitochondrial function mainly due to defects of the respiratory chain and consequent organellar energetics. This affects organs and tissues that require an efficient energy supply, such as brain and skeletal muscle. They are caused by mutations in both nuclear-and mitochondrial DNA (mtDNA)-encoded genes and their clinical manifestations show a great heterogeneity in terms of age of onset and severity, suggesting that patient-specific features are key determinants of the pathogenic process. In order to correlate the genetic defect to the clinical phenotype, we used a cell culture model consisting of fibroblasts derived from patients with different mutations in the mtDNA-encoded ND5 complex I subunit and with different severities of the illness. Interestingly, we found that cells from patients with the 13514A4G mutation, who manifested a relatively late onset and slower progression of the disease, display an increased autophagic flux when compared with fibroblasts from other patients or healthy donors. We characterized their mitochondrial phenotype by investigating organelle turnover, morphology, membrane potential and Ca 2+ homeostasis, demonstrating that mitochondrial quality control through mitophagy is upregulated in 13514A4G cells. This is due to a specific downregulation of mitochondrial Ca 2+ uptake that causes the stimulation of the autophagic machinery through the AMPK signaling axis. Genetic and pharmacological manipulation of mitochondrial Ca 2+ homeostasis can revert this phenotype, but concurrently decreases cell viability. This indicates that the higher mitochondrial turnover in complex I deficient cells with this specific mutation is a pro-survival compensatory mechanism that could contribute to the mild clinical phenotype of this patient. Mitochondrial disorders include a wide range of pathological conditions characterized by defects in organelle homoeostasis and energy metabolism, in particular in the electron transport chain (ETC) complexes. They are mostly caused by mutations in nuclear-or mtDNA-encoded genes of the respiratory chain complexes leading to a variety of clinical manifestations, ranging from lesions in specific tissues, such as in Leber's hereditary optic neuropathy, to complex multisystem syndromes, such as myoclonic epilepsy with ragged-red fibers, Leigh syndrome or the mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome (MELAS). 1, 2 Despite the detailed knowledge of the molecular defects in these diseases, their pathogenesis remains poorly understood. The heterogeneity of signs and symptoms depends on the diversity of the genetic background and on patient-specific compensatory mechanisms. Several studies investigated the consequences of nuclear DNA mutations on intracellular organelle physiology and Ca 2+ homeostasis. 3, 4 Here we analyzed a cohort of patients with mutations in the mtDNA-encoded ND5 subunit of NADH dehydrogenase in order to correlate the clinical phenotype with relevant intracellular parameters involved in mitochondrial physiology, such as the rate of autophagy and mitophagy fluxes, mitochondrial Ca 2+ dynamics, mitochondrial membrane potential and their functional relationship.
Mitochondrial Ca 2+ is a key regulator of organelle physiology, and impairment of cation homeostasis is a general feature of many pathological conditions, including mitochondrial diseases. 5 In addition, Ca 2+ uptake in this organelle has recently been demonstrated to be a fundamental regulator of autophagy. 6, 7 Autophagy is involved in physiological organelle turnover and in the removal of damaged or non-functional mitochondria by autophagy (called 'mitophagy') [8] [9] [10] [11] and is critical for organelle quality control. Given the pivotal role of mitochondrial Ca 2+ in the adaptation of adenosine triphosphate (ATP) production to cellular energy demand, the recent identification of the channel responsible for Ca 2+ entry into the organelle, the mitochondrial Ca 2+ uniporter (MCU), is instrumental for the understanding of the regulation of mitochondrial Ca 2+ transport in both physiological and pathological conditions. MCU was identified in 2011, 12, 13 and in the following years, molecular insight on its complex regulatory mechanism was obtained. The pore region is composed of MCU, its isoform MCUb 14 and essential MCU regulator (EMRE). 15 The channel is gated by the Ca 2+ -sensitive proteins mitochondrial Ca 2+ uptake 1 (MICU1) and MICU2 [16] [17] [18] [19] and further regulated by the SLC25A23 protein. 20 As to its cellular function, mitochondrial Ca 2+ has been shown to stimulate ATP production by positive regulation of three key dehydrogenases of the tricarboxylic acid cycle 21 and of the ETC. 22 In parallel, unregulated and sustained organelle Ca 2+ overload can also lead to the opening of the mitochondrial permeability transition pore, 23, 24 with consequent dissipation of mitochondrial membrane potential (ΔΨ mt ), release of caspase cofactors and activation of the apoptotic cascade. 5 Despite the significant molecular understanding of all these cellular processes, their role in the pathogenesis of mitochondrial diseases is still poorly understood. Here we investigated the interplay of these pathways and the possibility of their contribution to determine the severity of the pathology in a cellular model consisting of fibroblasts from patients carrying mutations in the mitochondrial ND5 gene.
Results
The autophagic flux is increased in cells with 13514A4G mutation. Given the wide variability in the clinical manifestations of complex I deficiency, we investigated whether a correlation between the severity of the clinical phenotype and mutation-specific cellular features could exist. We used a cellular model consisting of primary human skin fibroblasts derived from a cohort of four individuals (Pat#1 (patient 2 in Corona et al. 25 ), Pat#2 (patient 8 in Bugiani et al. 26 ), Pat#3 (patient 4 in Bugiani et al. 26 ), Pat#4 (patient 6 in Malfatti et al. 27 )) bearing mutations in the ND5 gene and from three independent healthy individuals as controls (Ctrl#1, Ctrl#2 and Ctrl#3). Pat#1 and Pat#2 are two unrelated patients with the same 13514A4G mutation, displaying atypical MELAS and Leigh syndrome, respectively, Pat#3 is a Leigh patient with a different mutation (13513G4A) and Pat#4 has the 13063G4A mutation and is affected by typical MELAS. Interestingly, the atypical phenotype of Pat#1 and Pat#2 is characterized by late onset, relatively slow progression of the neurological signs, normal plasma lactate and muscle morphology.
We first monitored the activation of autophagy, a key prosurvival process induced by a variety of stress conditions. We challenged patient and control fibroblasts with nutrient deprivation (Starvation) and monitored the appearance of autophagosomes by immunofluorescence of endogenous microtubule-associated protein 1A/1B light chain 3B (LC3).
In this experimental setup, the lipidated form of LC3, LC3-II, redistributes to autophagosomes, thus appearing as fluorescent dots inside the cells. 28 Interestingly, fibroblasts derived from both patients carrying the 13514A4G ND5 mutation (Pat#1 and Pat#2) clearly show, already in the fed condition, an increase in the number and size of the LC3-positive dots compared with controls, Pat#3 and Pat#4 cells (Figures 1a and b) . Thus the higher cellular autophagy correlates with the milder clinical phenotype, suggesting that this process could be protective during pathogenesis.
The induction of autophagosome formation observed in Pat#1 and Pat#2 cells could either be due to the cellular response to the pathological mutation or to a dysfunction in autophagy. In order to exclude a block in the recycling of the autophagic cargo, we evaluated the rate of the autophagic flux by incubating cells with the inhibitor of lysosomal acidification, chloroquine. 28 When looking at the fed condition, chloroquine induced a significant increase of autophagosome number and volume in both control and Pat#1 fibroblasts ( Figure 1c and Supplementary Figures S1a and b) . This indicates that the enhanced autophagy displayed by 13514A4G cells is not due to a decrease of autophagosome clearance. This was further confirmed by immunofluorescence staining of a different marker of autophagy sequestosome1 (SQSTM1/p62). This protein is incorporated into mature autophagosomes and degraded in autolysosomes, serving as a readout of the autophagic pathway. 29 The distribution of SQSTM1/p62 puncta perfectly matches that of LC3 puncta ( Supplementary  Figures S1c and d) . Its transcriptional upregulation in Pat#1 fibroblasts further demonstrates that 13514A4G cells have an increased autophagosome formation rather than a block in their degradation (Figure 1d) .
Additionally, we further confirmed that the increased autophagy is the direct consequence of the 13514A4G mutation by developing osteosarcoma cells with homoplasmic 13514A4G mutant mtDNA (13514A4G cybrids) or wt mtDNA (control cybrids). Our results clearly demonstrate that 13514A4G cybrids also have a basal increased number of autophagosomes compared with controls. In this cellular model, this is due to enhanced autophagy induction and not to a block in autophagosome clearance, as revealed by the chloroquine treatment (Figures 1e and f and Supplementary Figure S1e) .
Mitochondrial turnover through autophagy is higher in 13514A4G fibroblasts. In addition to its role in global cellular homeostasis, autophagy has an important role in removing damaged organelles. Mitochondria can be specific targets of this process through a selective process called mitophagy, which is critical for organelle quality control. 30, 31 We hypothesized that increased autophagy could represent an adaptive and/or compensatory mechanism aimed at eliminating dysfunctional and damaged organelles in 13514A4G fibroblasts, thus mitigating the effect of the pathological mutation. To test this hypothesis, we monitored the rate of mitochondria degradation via autophagy by implementing the recently described technique based on the protein Keima. Keima is a fluorescent protein characterized by a pH-dependent shift of its excitation peak (479 nm at neutral and 570 nm at acidic pH), 32 which is instrumental to monitor autophagic cargo delivery to lysosomes. Transfection Supplementary Table S1 . ***Po0.0001 compared with control.
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Mitochondria recycling in mitochondrial diseases V Granatiero et al of the mitochondria-targeted version of Keima in patient fibroblasts revealed a significant increase of the 'mitophagy index' (calculated as the ratio between images acquired at 570 and 479 nm excitation) selectively in 13514A4G cells (Figures 2a and b) . This points to an increased elimination of mitochondria through lysosomal degradation in Pat#1 and Pat#2. This was also confirmed by the enhanced translocation of Parkin to mitochondria 33, 34 in Pat#1 cells compared with the control cells (Supplementary Figure S2a) .
We also monitored the degradation of selected mitochondrial proteins in our system by blocking protein synthesis with cycloheximide. Despite no differences could be detected in the overall level of mitochondrial proteins in both resting conditions and after nutrient deprivation (Supplementary Figure  S2b) , MCU (in the inner mitochondrial membrane) and Tom20 (in the outer mitochondrial membrane (OMM)) show a much faster degradation in Pat#1 compared with control fibroblasts after blocking protein synthesis with cycloheximide, indicating a higher organelle turnover (Figure 2c) . 33, 34 Defective mitochondrial Ca 2+ homeostasis in 13514A4G fibroblasts. As previously reported, an impairment of mitochondrial Ca 2+ handling is associated with mitochondrial diseases. 35 Recently, Cardenas et al. 6 Figure S3d) and in permeabilized cells, where the contribution of plasma membrane or ER channels to the mitochondrial Ca 2+ response is absent (Supplementary Figure S3c) . In parallel, we performed [Ca 2+ ] measurements in wt and mutant cybrids. Even in this experimental setup, the 13514A4G mutation causes a specific decrease of mitochondrial Ca 2+ uptake (Supplementary Figures S3e-g ), further confirming the presence of a correlation between altered autophagy and impaired mitochondrial Ca 2+ dynamics associated with the 13514A4G mutation.
We next analyzed the signaling pathways linking mitochondrial Ca 2+ to autophagy by monitoring AMP-activated protein kinase (AMPK), the major metabolic sensor of AMP/ATP ratio. 6, 39, 40 Western blotting analysis of AMPK phosphorylation on Ser172 (p-AMPK) 40 revealed low p-AMPK level in resting conditions in control cells. Conversely, all patient-derived fibroblasts displayed a slight increase in p-AMPK levels, as expected in cells with deficiency of the respiratory chain complexes, but in Pat#1 this increase was dramatic. AMPK phosphorylation was induced after nutrient depletion in all the cells, except for Pat#1 fibroblasts, where phosphorylation level was already maximal (Figure 3c ). Other pathways involved in autophagy such as Akt, mammalian target of rapamycin and its target S6 were only modestly affected in 13514A4G fibroblasts (Supplementary Figure S4) . Thus the pattern of AMPK activation was directly correlated with the level ] mt rise in our system.
Impairment of the MCU complex in 13514A4G cells. To further dissect the molecular mechanisms underlying the impairment of mitochondrial Ca 2+ handling, we evaluated the major mitochondrial parameters involved in the control of organellar cation homeostasis, that is, (i) expression of the MCU complex components, (ii) ER-mitochondria contact sites, (iii) morphology and (iv) membrane potential.
The expression level of the MCU complex components showed small but significant differences. In particular, in Pat#1 and, to a lesser extent, in Pat#2, the positive regulators of MCU, MICU1 and EMRE were downregulated, while the negative regulator MICU2 was slightly increased (Figure 3d) . Importantly, this MCU complex remodeling was not present (except for EMRE) in Pat#3 and Pat#4, in line with the [Ca 2+ ] mt homeostasis data. In addition, we recently reported that MICU1 homodimer and MICU1/MICU2 heterodimer regulates MCU sensitivity to extramitochondrial [Ca 2+ ] and exert opposite effects on the activity of the channel (stimulatory for MICU1 and inhibitory for MICU2). 19 The analysis of the ratio between MICU1/MICU1 and MICU1/MICU2 dimers in nonreducing conditions showed that two bands were present in control fibroblasts, corresponding to the MICU1/MICU2 heterodimer and the MICU1 homodimer. Conversely, Pat#1 cells lacked the MICU1 homodimer (Supplementary Figure S3h) , which is responsible for the rapid and efficient mitochondrial Ca 2+ uptake. This remodeling of the MCU complex can, at least in part, explain the reduced organelle Ca 2+ transients observed in these cells. We next investigated the ER-mitochondria contact sites, a key determinant of mitochondrial Ca 2+ uptake in intact cells, by monitoring the expression of the components of the tethering complex in mutant and control fibroblasts. The protein levels of the best characterized ER-mitochondria tether, Mitofusin 2 (Mfn2), 41 as well as other proteins located at the interface between the organelles, such as SigmaR1, showed a significant and specific decrease in 13514A4G cells (Figure 4a ). In addition, the downregulation of Mfn2 transcript in Pat#1 cells suggests that this effect occurs at the transcriptional level (Supplementary Figure S5a) . Following this, we directly measured the formation of ER-mitochondria contact sites in Pat#1 and control cells by using a novel technique based on the split-green fluorescent protein (GFP) technology. An OMM-anchored GFP lacking the essential beta strand 11 (GFP 1-10) and an ER-anchored beta strand 11, both facing the cytosolic side, were expressed in our fibroblasts. These constructs are per se non-fluorescent, but they reconstitute a functional fluorescent GFP as they come in were harvested, and total proteins were extracted and subjected to western blotting analysis with antibodies against phosphorylated AMPK on Ser172 (p-AMPK), total AMPK and β-Tubulin. (d) Healthy donor (Ctrl)-and patient-derived (Pat) fibroblasts were harvested, and total proteins were extracted and subjected to western blotting analysis with antibodies against MCU, MICU1, MICU2, EMRE and β-Tubulin. Data are presented as mean ± S.E. Descriptive statistics can be found in Supplementary Table S1. *Po0.05; **Po0.001; ***Po0.0001 compared with control close proximity (i.e., at ER-mitochondria contact sites) (Calì et al., submitted manuscript). Consequently, the fluorescence intensity correlates with the extent of ER-mitochondria contact sites. As shown in Figures 4b and c , contacts between the two organelles are reduced in Pat#1 fibroblasts, in agreement with the decrease of mitochondrial Ca 2+ uptake detected in these cells.
Mitochondrial fragmentation was also assessed in Pat#1 cells by immunostaining of the mitochondrial marker Tom20. No major alterations of organelle morphology could be observed (Figure 4d) . Indeed, morphometric analysis of mitochondrial network showed no significant differences in mitochondrial volume and number (Figure 4e) .
Finally, ΔΨ mt , the main driving force for Ca 2+ entry into mitochondria, was monitored in control and Pat#1 fibroblasts using the lipophilic dye tetra-methyl-rhodamine-methyl ester. No differences were observed after treatment with the ATP synthase inhibitor oligomycin or the complex I inhibitor rotenone. After rotenone addition, both cell lines maintained their ΔΨ mt through the reverse activity of ATP synthase, as demonstrated by the collapse of ΔΨ mt induced by oligomycin (Figure 4f ). On the other hand, when applied first, oligomycin caused a slight ΔΨ mt increase, indicating that both control and Pat#1 cells possess a functional ETC and generate ΔΨ mt that is partly consumed by ATP synthesis through the mitochondrial ATP synthase (Figure 4g ). In addition, a slight increase in complex III and V could be noticed in Pat#1 fibroblasts (Supplementary Figure S5b) , which may at least in part explain the normal steady-state ΔΨ mt (Supplementary Figure S5c) .
Together these results suggest that both the remodeling of the MCU complex composition and the rearrangement Supplementary Table S1 . *Po0.05; **Po0.001; ***Po0.0001 compared with control of ER-mitochondria tethering contribute to the decrease in mitochondrial Ca 2+ uptake in 13514A4G cells.
Genetic and pharmacological manipulation of mitochondrial Ca 2+ uptake restores the normal autophagic flux in 13514A4G fibroblasts. In order to test the possibility that the lowering of mitochondrial Ca 2+ uptake is upstream of the increased autophagy in 13514A4G fibroblasts, we corrected the Ca 2+ signaling alteration by molecular (i.e., MCU overexpression) or pharmacological (i.e., treatment with compounds that enhance mitochondrial Ca 2+ uptake) approaches, and experimentally verified whether the normal autophagic flux was restored. MCU was overexpressed in both Ctrl#1 and Pat#1 fibroblasts leading to an increase of [Ca 2+ ] mt transients in resting as well as starved cells, restoring organellar Ca 2+ signals of 13514A4G cells to control levels (Figure 5a ). When we monitored the translocation of the autophagy marker LC3 in the same conditions, we found that induction of the autophagic flux inversely correlates with the amplitude of mitochondrial Ca 2+ signals (Figures 5b and c) . Most importantly, MCU overexpression in Pat#1 cells was able to restore AMPK phosphorylation to levels undistinguishable from control (Figure 5d ). To confirm this effect, we treated control and patient cells with two structurally different MCU activators, Kaempferol (a plantderived antioxidant flavonoid) 42 and SB202190 (also an inhibitor of p38 MAPK). 43 Both compounds enhanced mitochondrial Ca 2+ uptake in Pat#1 fibroblasts to values similar to control cells (Figure 6a) . Interestingly, Kaempferol and SB202190 treatments in patient cells restored autophagy to the level of resting control fibroblasts (Figures 6b and c) .
Finally, we tested cell viability in fibroblasts treated with the two compounds or overexpressing MCU. As expected, both of these conditions lowered cell viability in control cells, confirming the notion that sustained [Ca 2+ ] mt overload enhances cell death. 44, 45 More importantly, the same manipulations cause a much higher decrease of cell viability in Pat#1 cells (Figure 6d ). This indicates that the decrease of mitochondrial Ca 2+ uptake in 13514A4G fibroblasts is a pro-survival compensatory mechanism in these cells.
Discussion
Mitochondrial disorders caused by mutations in mtDNA affect approximately 1 in every 10 000 adults. 46, 47 The broad heterogeneity of clinical manifestations, in terms of severity, age of onset and prognosis, relies on the specific molecular defect, the complexity of mitochondrial genetics 48 and the individual genotypic differences. The large diversity, however, could also depend on the cellular mechanisms that allow to compensate for the respiratory deficiency or promote the turnover of the damaged mitochondria. Recently, autophagy has been recognized as an important response to energetic defects, 49 as well as the leading mechanism for eliminating damaged organelles. 30, 31 In addition, mitochondrial Ca 2+ signaling has a role in the regulation of autophagy. 6 This complex relationship could allow, in the context of a mitochondrial disorder, the triggering of a cellular response that compensate, at least in part, the energetic defect, dampening the clinical phenotype. In this work, we investigated autophagy and mitochondrial Ca 2+ signaling in human fibroblasts from control subjects and from a set of patients carrying mutations in the mtDNA-encoded ND5 subunit of the ETC complex I. [25] [26] [27] Despite the impaired complex I activity 25, 26 and the increased ROS production (data not shown), these cells do not show any major defects in resting ΔΨ mt (Supplementary Figure S5c) or in organelle morphology (Figures 4d and e) . However, we observed a marked increase of the autophagic flux in fibroblasts carrying the 13514A4G mutation (Figures 1a-d and Supplementary  Figures S1a-d) . Interestingly, both the patients with this specific mutation display atypical MELAS and Leigh syndromes, characterized by late onset, slow progression, normal plasma lactate level and muscle morphology.
We thus focused our study on the molecular mechanism underlying the exaggerated autophagic flux in 13514A4G cells and tested whether this could justify the milder phenotype associated with this mutation. Notably, a similar increase in autophagy was also observed in cybrids homoplasmic for the same mtDNA mutation. Even in this system, this was clearly due to an enhanced formation of autophagosomes rather than a decrease of their clearance (Figures 1e and f and Supplementary Figure S1e) . Importantly, the accelerated autophagy underlies a faster mitochondrial turnover in Pat#1 compared with Ctrl#1 cells, as revealed by the shorter lifespan of mitochondrial proteins (Figure 2c ) and by the increase of mitochondria delivered to the lysosome (Figures 2a and b) . However, no difference at the steady state could be observed in the overall mitochondrial mass (Figures 4d and e) or in the total amount of mitochondrial proteins (Supplementary Figure S2b) , suggesting that a compensatory upregulation of mitochondrial biogenesis matches the rapid elimination of mitochondria.
We then investigated the molecular basis of the enhanced autophagy in 13514A4G cells by combining the observations that mitochondrial Ca 2+ signals inhibits autophagy 6 with the previously reported defects of mitochondrial Ca 2+ homeostasis in mitochondrial disorders. 35 The analysis of Ca Figures S3e-g ). Accordingly, the p-AMPK, and consequently its activity, are higher in 13514A4G cells compared with control (Figure 3c ). This impairment of mitochondrial Ca 2+ uptake was due to both a decrease in interorganellar contact sites (Figures 4a-c) as well as to differences in the supramolecular organization of the MCU complex (Figure 3d ). However, as the defect in mitochondrial Ca 2+ accumulation in Pat#1 cells is also evident in permeabilized cells (Supplementary Figure S3c) , we conclude that the assembly of the MCU complex has a major role in lowering mitochondrial Ca 2+ uptake. In particular, Pat#1 and Pat#2 (but not Pat#3 and Pat#4) cells show a significant decrease of MICU1 and EMRE levels, known as positive MCU regulators, [15] [16] [17] [18] and an increase in the expression of MICU2. MICU2 is a negative MCU modulator as it forms the MICU1/ MICU2 heterodimer, thus sequestering MICU1 and preventing the MICU1 homodimer stimulatory activity on MCU, as we recently demonstrated. 19 Indeed, we detected the presence of MICU1 homodimers in control but not in Pat#1 fibroblasts (Supplementary Figure S3h) . Such an imbalance of MCU regulators could explain the reduced efficiency of mitochondrial Ca 2+ uptake in 13514A4G cells. The actual relevance of the correlation between autophagy and mitochondrial Ca 2+ homeostasis was corroborated by the demonstration that genetically or pharmacologically enhanced mitochondrial Ca 2+ uptake slows down the autophagic flux in 13514A4G cells (Figures 5 and 6) . Notably, long term treatment with these compounds as well as MCU overexpression decreased the cells' viability to a greater extent in 13514A4G At the end of treatments, the cell viability was determined using MTT assay. Cell viability is expressed as the percentage of the untreated control. Data are presented as mean ± S.E. Descriptive statistics can be found in Supplementary Table S1. *Po0.05; **Po0.001; ***Po0.0001 compared with control. ### Po0.0001 between the indicated groups cells compared with controls ( Figure 6d ). This supports the hypothesis that the lowering of mitochondrial Ca 2+ uptake is a compensatory, potentially beneficial cellular mechanism that, on the one hand, activates organelle turnover via autophagy and, on the other hand, reduces the efficiency of death pathways, to which cells harboring mtDNA defects are more vulnerable.
Overall, our data demonstrate that, in a model of a mitochondrial disorder displaying a relatively mild phenotype, organelle dysfunction is relieved by increasing mitochondrial turnover through mitophagy. This effect is triggered by decreasing mitochondrial Ca 2+ uptake, leading to upregulation of cellular catabolic processes through an AMPK-dependent mechanism. Consequently, selective stimulation of mitochondrial quality control could be a potentially promising approach to ameliorate the clinical manifestation of the most severe forms of mitochondrial diseases.
